We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
9 result(s) found, displaying 1 to 9
-
Australian public assessment report (AusPar)Pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat which has been approved for the treatment of adults with late onset Pompe disease (acid α-glucosidase [GAA] deficiency).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for POMBILITI cipaglucosidase alfa 105mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OPFOLDA miglustat 65 mg capsule bottle.
-
Prescription medicine registrationActive ingredients: cipaglucosidase alfa.
-
Prescription medicine registrationActive ingredients: miglustat.
-
Prescription medicine registrationActive ingredients: migalastat hydrochloride.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for GALAFOLD migalastat (as hydrochloride) 123 mg hard capsule blister pack.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Migalastat